Európai Unió -
svéd -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversering av neuromuskulär blockad som induceras av rocuronium eller vekuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Hollandia -
holland -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
sugammadex synthon 100 mg/ml, oplossing voor injectie
synthon b.v. microweg 22 6545 cm nijmegen - sugammadex natrium samenstelling overeenkomend met ; sugammadex - oplossing voor injectie - natriumhydroxide (e 524) ; stikstof (head space) (e 941) ; water voor injectie ; zoutzuur (e 507)
Európai Unió -
holland -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Európai Unió -
holland -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Európai Unió -
holland -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - omkering van neuromusculaire blokkade geïnduceerd door rocuronium of vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Európai Unió -
holland -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Belgium -
francia -
AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)
sugammadex reddy 100 mg/ml sol. inj. i.v. flac.
reddy holding gmbh - sugammadex sodique 108,8 mg/ml - eq. sugammadex 100 mg/ml - solution injectable - 100 mg/ml - sugammadex sodique 108.8 mg/ml - sugammadex
Európai Unió -
német -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Európai Unió -
német -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - umkehrung der neuromuskulären blockade durch rocuronium oder vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Európai Unió -
német -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.